Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...
H. Lundbeck A/S (Lundbeck) today announced that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented ...
Recent research has opened the debate on whether chemical imbalances cause depression, anxiety, and other conditions ...
Neurocrine Biosciences has rebounded 60% since April 2025, driven by robust Ingrezza sales and Crenessity's uncontested launch. Read why NBIX stock is a hold.
BuzzFeed on MSN
23 wholesome internet posts that actually made me smile instead of questioning humanity
I guarantee you won't stop smiling after seeing these! View Entire Post › ...
BuzzFeed on MSN
Workers are sharing the dead giveaways that a smart employee actually has no idea what they're doing
"Only response to anything going wrong is blaming people and yelling..." View Entire Post › ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results